4//SEC Filing
Federoff Howard J. 4
Accession 0001140361-21-013551
CIK 0000748592other
Filed
Apr 19, 8:00 PM ET
Accepted
Apr 20, 8:16 PM ET
Size
8.1 KB
Accession
0001140361-21-013551
Insider Transaction Report
Form 4
Federoff Howard J.
DirectorSee Remarks
Transactions
- Award
Stock Option
2021-04-16+2,627,915→ 2,627,915 totalExercise: $7.94Exp: 2031-04-15→ Common Stock (2,627,915 underlying) - Award
Stock Option
2021-04-16+597,253→ 597,253 totalExercise: $7.94Exp: 2031-04-15→ Common Stock (597,253 underlying)
Footnotes (2)
- [F1]The option vests and becomes exercisable over four years, with 656,979 shares vesting on April 16, 2022, 54,748 shares vesting on the sixteenth day of each month from May 2022 through March 2025, and the remaining 54,756 shares vesting on April 16, 2025, subject to continued service through each vesting date.
- [F2]The option vests and becomes exercisable in full upon the occurrence of the first approval by the Food and Drug Administration of an investigational new drug application in connection with that certain license among the Issuer, Factor Biosciences Therapeutics Limited and Novellus Therapeutics Limited, subject to continued service through such vesting date.
Documents
Issuer
Brooklyn ImmunoTherapeutics, Inc.
CIK 0000748592
Entity typeother
Related Parties
1- filerCIK 0001857261
Filing Metadata
- Form type
- 4
- Filed
- Apr 19, 8:00 PM ET
- Accepted
- Apr 20, 8:16 PM ET
- Size
- 8.1 KB